Enantioselective synthesis of azetidinone intermediate compounds

Description

BACKGROUND OF THE INVENTION

This invention relates to a process for producing intermediates for hydroxy-alkyl substituted azetidinones. Hydroxy-alkyl substituted azetidinones, for example, 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone, are described in U.S. Pat. No. 5,767,115. These compounds are useful as hypocholesterolemic agents in the treatment and prevention of atheroschlerosis.

Processes for preparing the corresponding azetidinone without the 3-hydroxy substituent are claimed in U.S. Pat. Nos. 5,728,827 and 5,561,227. Other processes for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)-propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone are disclosed in U.S. Pat. Nos. 5,631,365, 5,739,321 and 6,207,822 B1 (the '822 patent).

As per the procedure described in the '822 patent, the intermediate compound of Formula I, is protected with a suitable hydroxy-protecting group, such as a silyl protecting group such as that derived from chlorotrimethylsilane (TMSCI) or t-butyldimethyl-silyl chloride (TBDMSCI). This silylated product is further reacted with a silyl-enol ether silylating agent such as bistrimethylsilyl acetamide (BSA). A cyclizing agent such as a quaternary alkyl-, aryl-alkyl or arylalkyl-alkylammonium fluoride salt is then added to cause an intra-molecular cyclization of the previously silylated compound of Formula I. Finally, the protecting groups are removed from the cyclizied compound using conventional methods, such as treatment with a dilute acid, in order to form the hypocholesterolemic azetidinone having the Formula

SUMMARY OF THE INVENTION

This invention provides an improved, simple, high yielding process for preparing an intermediate compound useful in the production of azetidinones. The intermediate, a compound of Formula I:

is prepared by a process which comprises:

a) mixing a compound of Formula II

in tetrahydrofuran in the presence of an acid, or alternatively in tetrahydrofuran in the absence of an acid, to form a mixture;

b) combining the mixture of step a) with a catalyst selected from either (A) a compound selected from the group of compounds represented by Formula III, or (B) a compound of Formula IV,

wherein R

1

of Formula III is a (C

1

-C

6

)alkyl and wherein R and S indicate stereochemistry at the chiral carbons;

c) reducing the ketone adjacent to the p-fluorophenyl with a borane-tetrahydrofuran complex; and

d) quenching the reaction with MeOH.

DETAILED DESCRIPTION

In one embodiment, there is described herein a process for preparing a compound of Formula I

which comprises the steps (a)-(d) shown above.

In a preferred embodiment, the process comprises:

a) mixing a compound of Formula II in tetrahydrofuran in the presence of an acid to form a mixture;

b) combining the mixture of step a) with a catalyst selected from either (A) a compound selected from the group of compounds represented by Formula III, or (B) a compound of Formula IV

wherein R

1

of Formula III is a (C

1

-C

6

)alkyl and wherein R and S indicate stereochemistry at the chiral carbons;

c) reducing the ketone adjacent to the p-fluorophenyl with a borane-tetrahydrofuran complex; and

d) quenching the reaction with MeOH.

Except where stated otherwise, the following definitions apply throughout the present specification and claims. These definitions apply regardless of whether a term is used by itself or in combination with other terms. Hence the definition of “alkyl” applies to “alkyl” as well as to the “alkyl” portions of “alkoxy”, “alkylamino” etc.

“Alkyl” represents a straight or branched saturated hydrocarbon chain having the designated number of carbon atoms. Where the number of carbon atoms is not specified, 1 to 6 carbons are intended.

The acid in step a) is selected from the group consisting of BF

3

.OEt

2

, BCl

3

, p-toluene sulfonic acid, trifluoroacetic acid, methanesulfonic acid and camphorsulfonic acid.

If the catalyst of Formula IV is employed, it must be used in the presence of a trialkyl borate, preferably a trimethyl borate.

In another embodiment of the present invention, the ratio of the acid to the compound of Formula II is in a mole % of 1-10%, preferably 1-5%, more preferably in a mole % of 2-3%.

In another embodiment of the present invention, the ratio of the catalyst to the compound of Formula II of step b) is in a mole percent of 0.1-10%, preferably 1-5%, more preferably in a mole % of 2-3%.

In further embodiments of the present invention, the temperature of the reduction step c) is generally between −15 and 65° C., preferably between −10 and 55° C., more preferably between 0° and 30° C. and typically between 230 and 28° C.

In another embodiment of the invention, there is described a process for preparing a compound of Formula I

which process has no acid in step (a). The process, thus, comprises:

a) dissolving a compound of Formula II in tetrahydrofuran to form a mixture;

b) combining the mixture of step a) with a catalyst selected from either (A) a compound selected from the group of compounds represented by Formula III, or (B) a compound of Formula IV

wherein R

1

of Formula III is a (C

1

-C

6

)alkyl and wherein R and S indicate stereochemistry at the chiral carbons;

c) reducing the ketone adjacent to the p-fluorophenyl with a borane-tetrahydrofuran complex; and

d) quenching the reaction with MeOH.

In a preferred embodiment of the alternate process (with no acid in step (a)) described immediately above, the temperature of the reduction step c) is between 23 and 28° C.

In another embodiment of the alternate process (with no acid in step (a)) described immediately above, the ratio of the catalyst to the compound of Formula II of step b) is in a mole % of 0.1-10%, preferably 1-5%, more preferably in a mole % of 2-3%.

The present invention discloses a novel chemo selective and stereo selective reduction of the ketone adjacent to the p-fluorophenyl using a BH

3

-THF complex. In a previous process patent, U.S. Pat. No. 6,207,822 B1 (the '822 patent), the disclosure of which is incorporated herein by reference thereto, there is disclosed a reduction of said ketone using BH

3

Me

2

S (BMS) complex as a reducing agent. However, use of said BMS complex may lead to environmental concerns. The replacement of BMS with borane tetrahydrofuran complex eliminates the environmental issues raised by use of the BMS complex.

However, simple replacement of BH

3

Me

2

S with BH

3

-THF in the reduction generated a substantial amount of over-reduction of the amide bond, compared to the reduction of the ketone adjacent to the p-fluororophenyl, thus resulting in poor selectivity. Thus, initial experiments with BH

3

-THF yielded a desirable % of desired enantiomer (SS) to the undesired enantiomer (SR), however, the solution yield was not optimized due to the production of the above-noted over-reduced by-product from the amide. Applicants found, in the present process, that reversing the addition sequence surprisingly overcame the poor chemoselectivity in the reduction. The production of the over-reduced by-product from the amide was significantly reduced while at the same time resulting in high diasteroselectivity in the product.

The new process calls for adding BH

3

-THF to the solution of Formula II and (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborolidine (abbreviated as (R)-MeCBS) catalyst in THF (from Sigma-Aldrich, St. Louis, Mo.). Several experiments yielded results where the over-reduced by-product was minimized to <1% with diastereoselectivity of 97:3. In fact, the molar equivalent (eq) of BH

3

-THF was kept to ˜0.6 eq, while % molar yields were generally over 97%. Similar results could be obtained with a “in-situ” prepared catalyst using the compound of Formula IV (R-diphenylprolinol) and trimethylborate. (See reference: M. Masui, T. Shioiri, Synlett, 1997, 273).

The following examples used to prepare the compound of Formula I illustrate the present invention, although such examples should not be construed as limiting the scope of the invention. Alternative reagents and analogous processes within the scope of the invention will be apparent to those skilled in the art. The product solutions of the following examples (which contain the compound of Formula I) can be directly used as such in subsequent process steps to make hydroxy-alkyl substituted azetidinones, or in the alternative, the compounds of Formula I can be crystallized or isolated using methods known and recognized by one of ordinary skill in the art.

EXAMPLES

Abbreviations which are used in the description of the schemes, preparations and the examples are:

(R)-MeCBS=(R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborolidine

THF=tetrahydrofuran

HPLC=High Performance Liquid Chromatography

MeOH=methanol

Atm=atmospheres

mL=milliliters

g=grams

PTSA=p-toluene sulfonic acid

CSA=(1S)-(+)-10-camphorsulfonic acid

TFA=trifluoroacetic acid

de=difference between SS % and SR %

Example 1

Acid Absent in Step(a)

Fifty (50) g of the compound of Formula II was charged into a 1000 mL three necked round bottom flask equipped with a thermometer, N

2

inlet and addition funnel. 500 mL THF was charged to dissolve the 50 g of the compound Formula II at about 200 to 25° C. The batch was concentrated at 1 atm to a batch volume of about 150 mL. The temperature was adjusted to about 200 to 25° C. 4.2 mL of lab pre-formed (R)-MeCBS catalyst in toluene (3 mole %) was charged. 70.4 mL of 1M borane THF complex in THF solution (from Aldrich Chemical Company, Milwaukee, Wis.) was slowly charged over 1.5 hrs at temperature between about 23° and 28° C. The batch was sampled for HPLC to monitor the progress of the reaction. After the reaction was judged complete, 20 mL of MeOH was slowly charged to keep the temperature below 25° C. in order to quench the reaction. The batch was concentrated under vacuum to afford a batch volume of about 100 mL at a temperature below 40° C. 250 mL of toluene and a solution of 5 mL sulfuric acid in 100 mL water was charged. The mixture was agitated for about 10 min. and the batch was allowed to settle. The bottom acid layer was split off. 100 mL of water was charged to wash the batch twice. The batch was concentrated under vacuum at below 50° C. to afford a volume of about 100 mL. Results varied, but in general, yields of ˜99% and 95% de were obtained.

Example 2

Acid (pTSA) Present in Step (a)

Fifty (50) kg of the compound of Formula II and 0.8 kg of p-toluene sulfonic acid (PTSA) was charged into a 300 gallon glass lined reactor equipped with a thermocouple, N

2

inlet and feed tank. 267 kg of dry THF was charged to dissolve the 50 kg of the compound Formula II and the p-toluene sulfonic acid at about 20 to 25° C. The batch was concentrated at 1 atm to a batch volume of about 185 liters. The temperature was adjusted to about 20 to 25° C. 200 liters of THF was charged to the batch. The batch was concentrated at 1 atm to a batch volume of about 185 liters. The temperature was adjusted to about 20 to 25° C. 3.4 kg of pre-formed (R)-MeCBS catalyst in toluene (3 mole %) was charged. 70.3 kg 1M of borane THF complex in THF solution was slowly charged over 1.5 hours at a temperature range between about 23 and 28° C. The batch was sampled for HPLC to monitor the progress of the reaction. After the reaction was judged complete, using the same subsequent procedure as described in Example 1 (i.e. quenching with MeOH, vacuum concentration of the batch, etc., but in appropriate ratios of reagents for this example), the compound of Formula I was obtained in an average yield of 98.4%. A percentage yield of ˜97%, a solution yield of 100% and de of 93.6% was obtained.

Example 3

Acid Present in Step (a)

Fifteen (15) kg of the compound of Formula II was charged into a 50 gallon glass lined reactor equipped with a thermocouple, N

2

inlet and feed tank. 150 liters of dry THF was charged to dissolve the 15 kg of the compound Formula II at about 20 to 25° C. The batch was concentrated at 1 atm to a batch volume of about 55 liters. The temperature was adjusted to about 20 to 25° C. 1.5 kg of preformed (R)-MeCBS catalyst in toluene (3 mole %) was charged. 18.55 kg of 1M borane THF complex in THF solution was charged over 1.5 hours at a temperature range between about 23 and 28° C. The batch was sampled for HPLC to monitor the progress of the reaction. After the reaction was judged complete, using the same subsequent procedure as described in Example 1 (i.e. quenching with MeOH, vacuum concentration of the batch, etc., but in appropriate ratios of reagents for this example), the compound of Formula I was obtained in a yield of 100% with a de of 95.4%.

Example 4

Acid (CSA) Present in Step (a)

Thirty (30) g of the compound of Formula II and 0.386 g (2 mole %) of (1S)-(+)-10-camphorsulfonic acid (CSA) was charged in a 500 mL 3 necked round bottom flask equipped with a thermometer, N

2

inlet and addition funnel. 111 mL of dry THF was charged to dissolve the 30 g of the compound Formula II, and the (1S)-(+)-10-camphorsulfonic acid at about 20 to 25° C. 2.2 mL of pre formed (R)-MCBS catalyst in toluene (3 mole %) was charged. 39.9 mL of 1M borane THF complex in THF solution was slowly charged over 1.5 hours at a temperature range between about 23 and 28° C. The batch was sampled for HPLC to monitor the progress of the reaction. After the reaction was judged complete, using the same subsequent procedure as described in Example 1 (i.e. quenching with MeOH, vacuum concentration of the batch, etc., but in appropriate ratios of reagents for this example), the compound of Formula I was obtained. Results varied, but in general, ˜99% yield and ˜94% de were obtained.

Example 5

Using the method described above in example 4, other acids were substituted for CSA. This group of other acids included BF

3

.OEt

2

, BCl

3

, trifluoroacetic acid (TFA) or methansulfonic acid. Results varied, but in general, all yielded results with favorable SS:RS ratios of ˜95-97% to ˜3-5% and a % de range from ˜91 to ˜93.8%.

In general, chemical yields close to 97% and over were obtained.

Claims

1. A process for preparing a compound of Formula I is prepared by a process which comprises:a) mixing a compound of Formula II in tetrahydrofuran in the presence of an acid, or alternatively in tetrahydrofuran in the absence of an acid, to form a mixture;b) combining the mixture of step a) with a catalyst selected from either (A) a compound selected from the group of compounds represented by Formula III, or (B) a compound of Formula IV, wherein R1 of Formula III is a (C1-C6)alkyl and wherein R and S indicate stereochemistry at the chiral carbons;c) reducing the ketone adjacent to the p-fluorophenyl with a borane-tetrahydrofuran complex; and d) quenching the reaction with MeOH.
2. The process of claim 1 wherein the acid in step a) is BF3.OEt2, BCl3, p-toluene sulfonic acid, trifluoroacetic acid, methanesulfonic acid, or camphorsulfonic acid.
3. The process of claim 2 wherein the catalyst of Formula IV is employed in the presence of a trialkyl borate.
4. The process of claim 3 wherein said trialkyl borate is a trimethyl borate.
5. The process of claim 2 wherein said acid is present in a 1-10 mole percent ratio with respect to said compound of Formula II.
6. The process of claim 2 wherein said acid is present in a 1-5 mole percent ratio with respect to said compound of Formula II.
7. The process of claim 2 wherein said acid is present in a 2-3 mole percent ratio with respect to said compound of Formula II.
8. The process of claim 1 wherein said catalyst is present in a 0.1-10 mole percent ratio with respect to said compound of Formula II.
9. The process of claim 1 wherein said catalyst is present in a 1-5 mole percent ratio with respect to said compound of Formula II.
10. The process of claim 1 wherein said catalyst is present in a 2-3 mole percent ratio with respect to said compound of Formula II.
11. The process of claim 1 wherein the temperature in the reduction step c) is between −15 and 65° C.
12. The process of claim 1 wherein the temperature in the reduction step c) is between −10 and 55° C.
13. The process of claim 1 wherein the temperature in the reduction step c) is between 0 and 30° C.
14. The process of claim 1 wherein the temperature in the reduction step c) is between 23 and 28° C.
15. The process of claim 1, wherein acid is present in step (a).
16. The process of claim 1, wherein acid is absent in step (a).
17. The process of claim 16 wherein the temperature in the reduction step c) is between 23 and 28° C.
18. The process of claim 16 wherein said catalyst is present in a 0.1-10 mole percent ratio with respect to said compound of Formula II.
19. The process of claim 16 wherein said catalyst is present in a 1-5 mole percent ratio with respect to said compound of Formula II.
20. The process of claim 16 wherein said catalyst is present in a 2-3 mole percent ratio with respect to said compound of Formula II.

Parent Case Info

This application claims priority from pending U.S. Provisional Application Serial No. 60/279,288 filed on Mar. 28, 2001.

US Referenced Citations (29)

Number	Name	Date	Kind
4876365	Kirkup et al.	Oct 1989	A
5306817	Thiruvengadam et al.	Apr 1994	A
5561227	Thiruvengadam et al.	Oct 1996	A
5618707	Homann et al.	Apr 1997	A
5624920	McKittrick et al.	Apr 1997	A
5627176	Kirkup et al.	May 1997	A
5631365	Rosenblum et al.	May 1997	A
5633246	McKittrick et al.	May 1997	A
5656624	Vaccaro et al.	Aug 1997	A
5661145	Davis	Aug 1997	A
5688785	Vaccaro	Nov 1997	A
5688787	Burnett et al.	Nov 1997	A
5688990	Shankar	Nov 1997	A
5698548	Dugar et al.	Dec 1997	A
5728827	Thiruvengadam et al.	Mar 1998	A
5739321	Wu et al.	Apr 1998	A
5744467	McKittrick et al.	Apr 1998	A
5756470	Yumibe et al.	May 1998	A
5767115	Rosenblum et al.	Jun 1998	A
5846966	Rosenblum et al.	Dec 1998	A
5856473	Shankar	Jan 1999	A
5886171	Wu et al.	Mar 1999	A
5919672	Homann et al.	Jul 1999	A
6093812	Thiruvengadam et al.	Jul 2000	A
6096883	Wu et al.	Aug 2000	A
6133001	Homann et al.	Oct 2000	A
6207822	Thiruvengadam et al.	Mar 2001	B1
RE37721	Rosenblum et al.	May 2002	E
20020137689	Glombik et al.	Sep 2002	A1

Foreign Referenced Citations (42)

Number	Date	Country
2046823	Mar 1972	DE
0199630	Oct 1986	EP
0199630	Oct 1986	EP
0264231	Apr 1988	EP
0266896	May 1988	EP
0333268	Sep 1989	EP
0337549	Oct 1989	EP
0337549	Oct 1989	EP
0365364	Apr 1990	EP
0375527	Jun 1990	EP
0415487	Mar 1991	EP
0462667	Dec 1991	EP
0481671	Apr 1992	EP
0524595	Jan 1993	EP
0720599	Jul 1996	EP
136485	May 1981	JP
028057	Oct 1981	JP
180212	Mar 1986	JP
121479	Dec 1986	JP
219681	Apr 1987	JP
4356195	Sep 1992	JP
WO 9302048	Feb 1993	WO
WO 9414433	Jul 1994	WO
WO 9417038	Aug 1994	WO
WO 9508532	Mar 1995	WO
WO 9526334	Oct 1995	WO
WO 9616037	May 1996	WO
WO 9716455	May 1997	WO
WO 9721676	Jun 1997	WO
WO 9741098	Nov 1997	WO
WO 9746238	Dec 1997	WO
WO 9801100	Jan 1998	WO
WO 9805331	Feb 1998	WO
WO 9814179	Apr 1998	WO
WO 9831360	Jul 1998	WO
WO 9918072	Apr 1999	WO
WO 0020623	Apr 2000	WO
WO 0034240	Jun 2000	WO
WO 0060107	Oct 2000	WO
WO 0063703	Oct 2000	WO
WO 0250090	Jun 2002	WO
WO 02066464	Aug 2002	WO

Non-Patent Literature Citations (30)

Entry
Vaccaro et al., “Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors” Bioorganic & Medicinal Chemistry Letters 8:319-322 (1998).
Vaccaro et al., “Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar” Bioorganic & Medicinal Chemistry Letters 8:314-317 (1998).
Otto et al., Synthesis and stereochemistry of 3-(α-hydroxy=benzyl)-1,4-diphenyl-2-azetidinones, Chemical Abstracts 99(1) (Nov. 7, 1983).
Oguni et al., “Stereoselective syntheses of β-lactam derivatives by ultrasound promoted Reformatskii reaction” Chemical Abstracts 106(17) (Apr. 27, 1987).
Hoekman et al., “Synthesis of homologues of . . . Lactones” J. Agric. Food Chem. 30:920-924 (1982).
Otto et al., “Darstellung und stereochemie von-3-(α-hydroxybenzyl)-1,4-diphenyl-2-azetidinonen” Liebigs Ann. Chem. 1152-1161 (1983).
Georg et al., “3-(1′-hydroxyethyl)-2-azetidinones from 3-hydroxybutyrates and N-arylaldimines” Tetrahedron Letters 26(33):3903-3906 (1985).
Hart et al., “An enantioselective approach to carbapenem antibiotics: formal synthesis of (+)-thienamycin” Tetrahedron Letters 26(45):5493-5496(1985).
Panfil et al., “Synthesis of β-lactams from α,β-unsaturated sugar δ-lactones” Heterocycles, 24(6):1609-1617 (1986).
Ram et al., “Potential hypolipidemic agents . . . phenoxyalkanoates” Indian Journal of Chemistry 29B:1134-1137 (Dec. 1990).
Oppolzer et al., “Asymmetric diels-alder . . . Acrylates” Tetrahedron Letters 25(51):5885-5888 (1984).
“Ezetimibe: Hypolipidemic cholesterol absorption inhibitor” Drugs of the Future 25(7):679-685 (2000).
Rosenblum et al., “Discovery of 1-(4-Fluorophenyl) . . . Absorption” J. Med. Chem. 41:973-980 (1998).
Schnitzer-Polokoff et al., “Effects of ACYL-CoA . . . Hamsters” Comp. Biochem. Physiol. 99A(4):665-670 (1991).
Horie et al., “Hypolipidemic effects of NB-598 in dogs” Atherosclerosis 88:183-192 (1991).
Harwood et al., “Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818; tiqueside)” Journal of Lipid Research 34:377-395 (1993).
Salisbury et al., “Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461” Atherosclerosis 115:45-63 (1995).
Clader et al., “Substituted (1,2-diarylethyl)amide . . . Activity” J. Med. Chem. 38:1600-1607 (1995).
Vaccaro et al., “2-Azetidinone Cholesterol Absorption . . . Ring” Bioorganic & Medicinal Chemistry 6:1429-1437 (1998).
Sybertz et al. “SCH 48461, a novel inhibitor of cholesterol absorption” Elsevier Science, Atherosclerosis X, 311-315(1995).
Wu et al., “A Novel One-Step diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application to the Total Synthesis of Cholesterol Absorption Inhibitors” J. Am. Chem. Soc. (1999).
Ha et al., “N-Trimethylsilyl Imines: Applications to the Synthesis of β-Lactams” J. Am. Chem. Soc. 106(17):4819-4825 (1984).
Wentrup et al., “A stereocontrolled synthesis of (+)-Thienamycin” J. Am. Chem. Soc. 102:6161-6163 (1980).
Bringmann et al., “The directed cleavage of . . . β-lactams” Synthesis 829-831 (Oct. 1991).
Colvin et al., “Reaction of silyl . . . azetidin-2-ones” J. Chem. Soc., Chem. Commun. 539-540 (1985).
Aldrich Chemical Catalog, p. 191 (1994).
Corriu et al., “Activation of silicon-hydrogen, silicon-oxygen, silicon-nitrogen bonds in heterogeneous phase” Tetrahedron, 39(6):999-1009 (1983).
Bouzard et al., “Utilisation du fluorure . . . Pyridone-4-Carboxylique-3” Tetrahedron Let. 29(16):1931-1934 (1988).
The Condensed Chemical Dictionary, 10th Ed. p. 48 (1980).
Wallbaum S. et al., 1992, “Asymmetric Syntheses with Chiral Oxazaborolidines”, 3:12—1476-1495.

Provisional Applications (1)

	Number	Date	Country
	60/279288	Mar 2001	US

Enantioselective synthesis of azetidinone intermediate compounds

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications